Why the study?
Do glycoprotein IIb/IIIa inhibitors reduce death, myocardial infarction, and urgent or repeat coronary revascularization in patients with acute coronary syndromes or undergoing percutaneous coronary intervention?
Do glycoprotein IIb/IIIa inhibitors reduce death, myocardial infarction, and urgent or repeat coronary revascularization in patients with acute coronary syndromes or undergoing percutaneous coronary intervention?
Glycoprotein IIb/IIIa inhibitors reduce ischemic events in ACS and PCI but require careful monitoring for bleeding and thrombocytopenia.
Answers are grounded in this paper and cite their sources.
Supports ischemic event reduction with glycoprotein IIb/IIIa inhibitors in ACS/PCI; leaves open optimal bleeding risk mitigation in contemporary practice.
The advent of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes and in those undergoing percutaneous coronary intervention has added a new dimension to antiplatelet therapy. These agents work by blocking the final common pathway of platelet aggregation in thrombus formation. This is achieved by preventing the binding of fibrinogen to the activated glycoprotein IIb/IIIa receptors on the platelet surface. Three agents are currently licensed for use: abciximab, eptifibatide and tirofiban. Clinical trials have demonstrated a reduction in death, myocardial infarction and urgent or repeat coronary revascularization in those who received these agents, compared with placebo. Two potential complications with these agents are bleeding, particularly from the femoral artery access point, and thrombocytopenia. For nurses working in cardiac catheterization laboratories and cardiovascular wards, there needs to be an awareness of the benefits of receiving these agents, of which patients should receive them, and of their effect on platelets.
No takes yet. Share an insight, caveat, or question.
Kate O’Donovan (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: